Moffitt Cancer Center researchers developed a tool aimed at guiding treatment and improving care for patients with prostate cancer.
The questionnaire, called the "Functional Assessment of Cancer Therapy-Radionuclide Therapy," is a 15-question survey that prompts patients to report on the symptoms and side effects associated with prostate cancer therapies called radionuclide therapy.
The questionnaire will help clinicians and patients better understand how cancer and its treatment can affect their quality of life, according to a Jan. 19 news release from the organization.